PharmaMarketing Summit Travels on May 11 -12, 2023 to an Exquisite Location: The Four Seasons Hotel Westlake Village, Westlake Village, CA, US

We are thrilled to announce that the PharmaMarketing Summit travels on 11 – 12 May 2023 to an exquisite location the Four Seasons Hotel Westlake Village, Westlake Village, CA, US.

The PharmaMarketing summit unites leading pharmaceutical marketing executives and innovative sponsors in an exclusive networking environment. The Summit’s content is aligned with key pharma marketing challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers.

The PharmaMarketing provides the opportunity to attendees to pre-schedule one-on-one physical business meetings with key leading and forward-thinking executives.

Delegates include:

  • CEO and Founder – Ascertain Biosciences
  • Head of Digital Innovation & Marketing Operations – Azurity Pharmaceuticalss
  • VP, Global Market Access – Bayer AG
  • Director of Marketing, HAE Franchise – CSL Behring
  • Director, Medical Science Liaison – Immunovant, Inc.
  • North America Brand Lead, Rare Disease Franchise – Kyowa Kirin
  • Vice President – Global Commercial Operations – Merck

To find more information you can visit https://events.marcusevans-events.com/pharmamarketing-may2023/ or contact directly Isidora Avraam at isidoraa@marcusevanscy.com. #MKTSummit

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version